Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR3A | P46098 | 3/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698755 | 0.87 | HTR1A (0.46) | HTR2CHTR6HTR1AHTR3ADRD2 | |
| SCHEMBL4698293 | 0.86 | HTR2C (0.60) | HTR2CSLC6A2SLC6A4SLC6A3SOS1 | |
| SCHEMBL4699352 | 0.85 | DRD2 (0.44) | HTR2CHTR6HTR1AHTR3ADRD2 | |
| SCHEMBL4698299 | 0.85 | HTR2C (0.49) | HTR2CHTR6HTR1AHTR3AALOX5AP | |
| SCHEMBL4701205 | 0.83 | HTR2C (0.42) | HTR2CHTR6HTR1AHTR3ADRD2 | |
| SCHEMBL4700434 | 0.83 | HTR2C (0.52) | HTR2CSOS1HTR6HTR1AHTR3A | |
| SCHEMBL4701397 | 0.82 | HTR2C (0.48) | HTR2CSLC6A4HTR6HTR1AHTR3A | |
| SCHEMBL4698796 | 0.81 | HTR1A (0.47) | HTR2CHTR6HTR1AHTR3ADRD2 | |
| SCHEMBL4698848 | 0.81 | HTR1A (0.49) | HTR2CHTR6HTR1AHTR3ADRD2 | |
| SCHEMBL4699881 | 0.81 | DRD2 (0.47) | HTR2CHTR6HTR1AHTR3ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | claimed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | claimed |
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | disclosed |
| EP-1613594-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087662-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | TPH1, HTR2C, HTR1D | HTR2C 2/4885SLC6A2 23/4885SLC6A4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.